AstraZeneca: IMFINZI And IMJUDO With Chemotherapy Approved In The US For Patients With Metastatic Non-Small Cell Lung Cancer
November 12, 2022
November 12, 2022
WILMINGTON, Delaware, Nov. 12 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's IMFINZI(R) (durvalumab) in combination with IMJUDO(R) (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
The approval by the Food and Drug Administration (FDA) was based on the results from the POSEIDON Phase III . . .
AstraZeneca's IMFINZI(R) (durvalumab) in combination with IMJUDO(R) (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
The approval by the Food and Drug Administration (FDA) was based on the results from the POSEIDON Phase III . . .